Paper Details

  1. Home
  2. Paper Details

Identification of Novel PPARα/γ Dual Agonists by Virtual Screening of Specs Database.

Author: ChengXian-Chao, FuJing-Wei, LiuXin, WangRun-Ling, WangShu-Qing, XuWei-Ren, ZhangJun

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study identified potential PPARα/γ dual agonists for treating type 2 diabetes mellitus (T2DM) using docking, ADMET prediction, and molecular dynamics simulations. Representative compounds ZINC36517927 and ZINC13573581 displayed higher binding scores, better pharmacokinetic profiles, and predicted affinity with PPARα/γ. These findings suggest an approach to identify novel high-efficiency PPARα/γ dual agonists for T2DM treatment.
Paper Details　
Original Abstract of the Article :
Rosiglitazone was restricted clinically due to the side effects such as edema, weight gain and cardiac failure mainly attributing to the single and selective PPARγ activation. Nowadays, multi-targeted PPARs agonists remained to be a hot topic in the antidiabetic medicinal chemistry field. In this pa...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.2174/1386207319666160615013027

データ提供：米国国立医学図書館（NLM）

PPARα/γ Dual Agonists: A Quest for New Diabetes Treatments in the Desert of Metabolism

Type 2 diabetes, a metabolic disorder affecting millions, can be a daunting challenge. Imagine traversing a vast desert with limited resources. This research explores the potential of PPARα/γ dual agonists, a new class of drugs, to help regulate blood sugar levels and combat type 2 diabetes. The researchers used a virtual screening approach to identify potential drug candidates, like using a map to identify the best route to an oasis in the desert.

PPARα/γ Dual Agonists: A New Hope for Diabetes Management

The researchers identified several promising drug candidates that demonstrated strong binding affinity to both PPARα and PPARγ, key proteins involved in regulating blood sugar levels. This is like finding a hidden oasis in the desert, offering a potential solution to the challenges of diabetes management.

A New Era of Diabetes Treatment: A Desert Oasis of Hope

This research underscores the potential of PPARα/γ dual agonists to become a new cornerstone of diabetes treatment. By targeting multiple pathways involved in blood sugar regulation, these drugs may offer a more effective and personalized approach to diabetes management.

Dr.Camel's Conclusion

This research is a beacon of hope in the vast desert of diabetes research, highlighting the potential of PPARα/γ dual agonists to revolutionize diabetes treatment. Further research and clinical trials are needed to confirm their efficacy and safety, but this research offers a glimpse into a future where diabetes management could be more effective and personalized.

Date :
  1. Date Completed 2017-08-03
  2. Date Revised 2019-09-23
Further Info :

Pubmed ID

27316369

DOI: Digital Object Identifier

10.2174/1386207319666160615013027

Related Literature

Article Analysis
・Side Effects of rosiglitazone
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.